Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Abstract

BACKGROUND:

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce chronic inflammation and risk of many cancers, but their effect on risk of hepatocellular carcinoma (HCC) and death due to chronic liver disease (CLD) has not been investigated.

METHODS:

We analyzed prospective data on 300504 men and women aged 50 to 71 years in the National Institutes of Health-AARP Diet and Health Study cohort and linked self-reported aspirin and nonaspirin NSAID use with registry-confirmed diagnoses of HCC (n=250) and death due to CLD (n=428, excluding HCC). We calculated hazard rate ratios (RRs) and their two-sided 95% confidence intervals (CIs) using Cox proportional hazard regression models with adjustment for age, sex, race/ethnicity, cigarette smoking, alcohol consumption, diabetes, and body mass index. All tests of statistical significance were two-sided.

RESULTS:

Aspirin users had statistically significant reduced risks of incidence of HCC (RR = 0.59; 95% CI = 0.45 to 0.77) and mortality due to CLD (RR = 0.55; 95% CI = 0.45 to 0.67) compared to those who did not use aspirin. In contrast, users of nonaspirin NSAIDs had a reduced risk of mortality due to CLD (RR = 0.74; 95% CI= 0.61 to 0.90) but did not have lower risk of incidence of HCC (RR = 1.08; 95% CI = 0.84 to 1.39) compared to those who did not use nonaspirin NSAIDs. The risk estimates did not vary in statistical significance by frequency (monthly, weekly, daily) of aspirin use, but the reduced risk of mortality due to CLD was statistically significant only among monthly users of nonaspirin NSAIDs compared to non-users.

CONCLUSIONS:

Aspirin use was associated with reduced risk of developing HCC and of death due to CLD whereas nonaspirin NSAID use was only associated with reduced risk of death due to CLD.

• Authors: Vikrant V Sahasrabuddhe, Munira Z Gunja, Barry I Graubard, Britton Trabert, Lauren M Schwartz, Yikyung Park, Albert R Hollenbeck, Neal D Freedman, Katherine A McGlynn
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 104 Issue 23 Pg. 1808-14 (Dec 05 2012) ISSN: 1460-2105 [Electronic] United States
• PMID: 23197492 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Cyclooxygenase Inhibitors
• Cyclooxygenase 1
• Cyclooxygenase 2
• PTGS1 protein, human
• PTGS2 protein, human
• Aspirin

Topics

• Aged
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
• Aspirin (administration & dosage)
• Carcinoma, Hepatocellular (epidemiology, mortality)
• Chronic Disease
• Comorbidity
• Cyclooxygenase 1 (drug effects)
• Cyclooxygenase 2
• Cyclooxygenase Inhibitors (administration & dosage)
• Female
• Humans
• Incidence
• Liver Diseases (epidemiology, mortality)
• Liver Neoplasms (epidemiology)
• Male
• Middle Aged
• Odds Ratio
• Proportional Hazards Models
• Prospective Studies
• Risk Assessment
• Risk Factors
• United States (epidemiology)